<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02983097</url>
  </required_header>
  <id_info>
    <org_study_id>DSHNHL 2008 R6</org_study_id>
    <secondary_id>2009-010824-25</secondary_id>
    <nct_id>NCT02983097</nct_id>
  </id_info>
  <brief_title>Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP</brief_title>
  <acronym>R²-DHAP</acronym>
  <official_title>Open-label, Multicenter Phase I/II Study: Salvage Therapy of Progressive and Relapsed Aggressive Non-Hodgkin-Lymphoma by Combination of Lenalidomide (Revlimid®) With Rituximab, Dexamethason, High-dose ARA-C and Cisplatinum (R²-DHAP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to evaluate efficacy and safety of the combination of lenalidomide,
      an immunomodulatory drug (IMiD) with a standard immunochemotherapy treatment, called R-DHAP.
      R-DHAP consists of a monoclonal antibody called Rituximab and chemotherapy consisting of
      Dexamethasone, high dose Cytarabine, often called Ara-C, and platinum based chemotherapy,
      either cisplatinum, or, if treatment with cisplatinum is contraindicated, carboplatinum.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1/2 study to evaluate the efficacy and safety of lenalidomide added to a
      standard chemotherapy regime of R-DHAP (Rituximab, Dexamethasone, high-dose Cytarabine,
      Cis/Carboplatinum) in the treatment of relapsed or refractory high-grade B-cell
      non-hodgkin-lymphoma (NHL).

      The study hypothesis is that the combination of lenalidomide with standard immunochemotherapy
      will lead to an overall response rate of at least 60%. In this study, 3 rounds of
      immunochemotherapy in combination with lenalidomide will be administered. After the first or
      second round of therapy, peripheral hematopoetic stem cells will be harvested. Consolidation
      treatment with autologous or allogenic peripheral blood stem cell transplantation is
      recommended in all patients suitable, but is not part of the study.

      In phase 1, up to six cohorts of at least 6 patients each will be treated with the study
      therapy, with lenalidomide in increasing dosages, to determine the maximum tolerated dose
      (MTD).

      In phase 2, 50 patients will be treated with the MTD. Efficacy and safety will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Phase II: no scientific interests are given anymore
  </why_stopped>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">April 28, 2015</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>78 - 85 days + 2 years Follow Up</time_frame>
    <description>The percentage of patients which showed either a partial remission (PR), a complete remission with remaining uncertainty (CRu) or a complete remission (CR) after study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>78 - 85 days</time_frame>
    <description>The maximum dose of lenalidomide tolerated with acceptable toxicity during phase 1 of this study. The MTD established in phase 1 of this study will be administered to 50 patients in phase 2 of this study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of complete remission</measure>
    <time_frame>78 - 85 days + 2 years Follow Up</time_frame>
    <description>laboratory, BM biopsy, imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of primary progression</measure>
    <time_frame>78 - 85 days + 2 years Follow Up</time_frame>
    <description>The rate of patients which show progressive disease (PD) during or directly after study therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of treatment related deaths</measure>
    <time_frame>78 - 85 days + 2 years Follow Up</time_frame>
    <description>check survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse Rate</measure>
    <time_frame>78 - 85 days + 2 years Follow Up</time_frame>
    <description>laboratory, BM biopsy, imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>78 - 85 days + 2 years Follow Up</time_frame>
    <description>check survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>78 - 85 days + 2 years Follow Up</time_frame>
    <description>laboratory, BM biopsy, imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tumour control</measure>
    <time_frame>78 - 85 days + 2 years Follow Up</time_frame>
    <description>laboratory, BM biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>feasibility of stem cell mobilization</measure>
    <time_frame>78 - 85 days + 2 years Follow Up</time_frame>
    <description>The collection of peripheral stem cells is needed to be able to offer the patient high dose chemotherapy followed by autologous stem cell transplantation after the study treatment has ended.
Stem cell collection of &lt;2.0 *10e6 CD34+cells/kg will be considered insufficient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of non-hematological toxicities &gt; grade 2 CTC</measure>
    <time_frame>78 - 85 days + 2 years Follow Up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence and duration of neutropenia and thrombopenia grade 4</measure>
    <time_frame>78 - 85 days + 2 years Follow Up</time_frame>
    <description>laboratory WBC &lt; 1.0 /nl or Plt &lt; 25 /nl</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Diffuse Large B-cell Lymphoma (DLBCL)</condition>
  <condition>Follicular Lymphoma Grade III (FL III°)</condition>
  <condition>Mantle Cell Lymphoma (MCL), Blastoid Variant</condition>
  <condition>Burkitt Lymphoma (BL)</condition>
  <condition>Aggressive Marginal Zone Lymphoma (MZL)</condition>
  <arm_group>
    <arm_group_label>R²-DHAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination treatment with immunochemotherapy (R-DHAP) and lenalidomide
Dosage:
Rituximab 375 mg/m² day 1, i.v. Cisplatin 100 mg/m² or Carboplatin AUC5 day 2, i.v. Cytarabine 2000 mg/m², administered twice, on day 3, i.v. Dexamethasone 40 mg, days 2-5, p.o. Lenalidomide 5-20 mg, day 1-7 / day-6-+7, p.o. PEG-Filgrastim 6 mg, day 6, s.c.
peripheral stem cell collection after cycle 1 or 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab 375 mg/m²</description>
    <arm_group_label>R²-DHAP</arm_group_label>
    <other_name>MabThera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatinum 100 mg / m²</description>
    <arm_group_label>R²-DHAP</arm_group_label>
    <other_name>Cisplatinum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatinum AUC5</description>
    <arm_group_label>R²-DHAP</arm_group_label>
    <other_name>Carboplatinum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone 40 mg</description>
    <arm_group_label>R²-DHAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Cytarabine 2000 mg/m², administered twice</description>
    <arm_group_label>R²-DHAP</arm_group_label>
    <other_name>Cytarabin</other_name>
    <other_name>Ara-C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>5-20 mg administered either d1-d7, or d-6-d7</description>
    <arm_group_label>R²-DHAP</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PegFilgrastim</intervention_name>
    <description>PegFilgrastim 6 mg</description>
    <arm_group_label>R²-DHAP</arm_group_label>
    <other_name>Neulasta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral stem cell collection</intervention_name>
    <description>collection of peripheral stem cells for autologous stem cell transplantation</description>
    <arm_group_label>R²-DHAP</arm_group_label>
    <other_name>peripheral stem cell apheresis</other_name>
    <other_name>hematopoetic stem cell apheresis</other_name>
    <other_name>peripheral hematopoetic stem cell apheresis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Age: 18-70

        Risk groups: All risk groups

        histology: diagnosis or a recurrent or primary progressive aggressive b-cell non-hodgkin
        lymphoma, in particular

          -  follicular lymphoma grade III

          -  diffuse large b-cell lymphoma

          -  burkitt lymphoma

          -  mantle cell lymphoma, blastoid variant

          -  aggressive marginal zone lymphoma

        Performance status: ECOG 0-2

        Criteria for women of childbearing potential:

        Women of childbearing potential have to:

          -  understand the teratogenic risk associated with the study therapy, especially
             lenalidomide

          -  understand the need of reliable, uninterrupted birth control from 4 weeks prior to the
             start of the study drug, during the duration of the study treatment, and 4 weeks after
             completion of study treatment, and be able to reliably use birth control, except if
             the patient commits to absolute sexual abstinence, confirmed on a monthly basis

        The following are effective methods of contraception:

          -  implant

          -  levonorgestrel-releasing intrauterine system (IUS)

          -  medroxyprogesterone acetate depot

          -  tubal sterilisation

          -  sexual intercourse with a vasectomised male partner only, vasectomy must be confirmed
             by two negative semen analyses

          -  ovulation-inhibitory progesterone-only pills If not established on effective
             contraception, the female subject must be referred to an appropriately trained health
             care professional for contraceptive advice in order that contraception can be
             initiated.

          -  Understand that even if she has amenorrhea, she must follow all the advice on
             effective contraception

          -  Understand the potential consequences of pregnancy and the need to rapidly consult if
             there is a risk of pregnancy.

          -  Agree to have a medically supervised pregnancy test with a minimum sensitivity of 25
             mIU/ml on the day of the study visit or in the 3 days prior to the study visit once
             the subject has been on effective contraception for at least 4 weeks. This requirement
             also applies to women of childbearing potential who practice complete and continued
             abstinence. The test should ensure the subject is not pregnant when she starts
             treatment.

          -  Agree to have a medically supervised pregnancy test every 4 weeks including 4 weeks
             after the end of study treatment, except in the case of confirmed tubal sterilization.
             These pregnancy tests should be performed on the day of the study visit or in the 3
             days prior to the study visit. This requirement also applies to women of childbearing
             potential who practice complete and continued abstinence.

        Male patients have to:

          -  Agree to use condoms throughout study drug therapy, during any dose interruption and
             for one week after cessation of study therapy if their partner is of childbearing
             potential and has no contraception.

          -  Agree not to donate semen during study drug therapy and for one week after end of
             study drug therapy.

        All patients have to:

          -  Agree to abstain from donating blood while taking study drug therapy and for one week
             following discontinuation of study drug therapy.

          -  Agree not to share study medication with another person and to return all unused study
             drug to the investigator

        Patients must be able to take low molecular weight heparin as prophylactic anticoagulation

        Written informed consent is necessary

        Exclusion Criteria:

          -  pregnant or lactating females

          -  already initiated salvage lymphoma therapy (except prephase as specified in this
             study)

          -  serious accompanying disorder or impaired organ function causing significant clinical
             problems and reduced lyfe expectancy, in particular: heart: angina pectoris CCS&gt;2
             cardiac failure NYHA&gt;2 and/or EF&lt;45% lungs: FeV1&lt;60%, diffusion capacity &lt;50% of the
             reference values kidneys: creatinine&gt;2 times the upper reference limit liver:
             bilirubin &gt;2 times the upper reference limit

          -  platelets &lt;80000/mm³, leukocytes &lt;2500/³

          -  CNS involvement of lymphoma

          -  known hypersensitivity to the medications to be used

          -  known HIV-positivity

          -  suspicion that patient compliance will be poor, especially that rules for effective
             contraception will not be followed

          -  simultaneous participation in other treatment studies

          -  non-conformity to eligibility criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertram Glaß, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AK St.Georg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diakonie Krankenhaus Bremen</name>
      <address>
        <city>Bremen</city>
        <zip>28239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz</name>
      <address>
        <city>Chemnitz</city>
        <zip>09113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt/Oder</name>
      <address>
        <city>Frankfurt/Oder</city>
        <zip>15236</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Altona</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westpfalz Klinikum</name>
      <address>
        <city>Kaiserslautern</city>
        <zip>67665</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Karlsruhe</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU Klinikum München-Großhadern</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.lymphome.de/</url>
    <description>Homepage of the &quot;Kompetenznetz Maligne Lymphome&quot;</description>
  </link>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2013</study_first_submitted>
  <study_first_submitted_qc>December 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2016</study_first_posted>
  <last_update_submitted>January 17, 2018</last_update_submitted>
  <last_update_submitted_qc>January 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lymphoma</keyword>
  <keyword>relapse</keyword>
  <keyword>recurrence</keyword>
  <keyword>progress</keyword>
  <keyword>progressive</keyword>
  <keyword>b-cell lymphoma</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>IMiD</keyword>
  <keyword>Salvage chemotherapy</keyword>
  <keyword>peripheral stem cell mobilization</keyword>
  <keyword>lenalidomide</keyword>
  <keyword>Rituximab</keyword>
  <keyword>CD20</keyword>
  <keyword>Cytarabine</keyword>
  <keyword>Ara-C</keyword>
  <keyword>platinum-based chemotherapy</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Cisplatinum</keyword>
  <keyword>Carboplatinum</keyword>
  <keyword>Dexamethasone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

